{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:01:28Z","timestamp":1790557288028,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303084"],"award-info":[{"award-number":["82303084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360519"],"award-info":[{"award-number":["82360519"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor with a poor prognosis, marked by a postoperative recurrence rate of 50\u201360% and a 5-year survival rate of 8\u201330%. Abnormal tumor metabolism, particularly, amino acid metabolism, plays a key role in malignant progression. However, the molecular mechanisms linking amino acid metabolism to ICC progression remain unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Bioinformatics was used to identity the key amino acid metabolism related gene in ICC, qRT-PCR, western blotting and immunohistochemical (IHC) were used to detect the expression of ANXA1 in normal tissues or ICC tissues and cells at mRNA and protein levels. The effects of ANXA1 on the proliferation ability of ICC in vitro and in vivo were investigated using CCK8, cloning formation experiment, EdU, IHC, nude mice subcutaneous tumorigenesis model. Immunoprecipitation, mass spectrometry analysis, protein ubiquitin level detection test, immunofluorescence co-localization, and redox stress metabolite detection test were used to explore the metabolism-related regulatory mechanism of ANXA1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>we employed bioinformatics analysis to classify ICC into metabolic subgroups with distinct prognoses and identified the associated biomarker Annexin A1(ANXA1), whose high expression is correlated with poor prognosis and promotes ICC development. Mass spectrometry analysis revealed that ANXA1 interacts with the key enzyme in glutamine metabolism, glutamic-oxaloacetic transaminase 1(GOT1). Through in vitro and in vivo experiments, overexpressed ANXA1 stabilizes GOT1 by recruiting the deubiquitinase USP5. This stabilization enhances glutamine uptake, as well as the production of aspartate and glutamate, which in turn reduces oxidative stress, thereby promoting tumor cell growth. Moreover, knockdown of ANXA1 combined with glutamine uptake inhibition significantly suppressed ICC cell proliferation and Inhibited subcutaneous tumor formation and growth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that the ANXA1\/USP5\/GOT1 axis promotes glutamine metabolism and ICC proliferation and growth. Inhibiting ANXA1 alongside glutamine uptake inhibition offers a promising strategy for treating ICC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03400-z","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:59:50Z","timestamp":1747627190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ANXA1 promotes intrahepatic cholangiocarcinoma proliferation and growth by regulating glutamine metabolism through GOT1 stabilization"],"prefix":"10.1186","volume":"44","author":[{"given":"Yanyu","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"3400_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. Jan. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","DOI":"10.3322\/caac.21708"},{"key":"3400_CR2","doi-asserted-by":"publisher","unstructured":"Chang Y-J, Chang Y-J, Chen L-J. Prognostic factors in patients with intrahepatic cholangiocarcinoma. Sci Rep. Aug. 2024;14(1):19084. https:\/\/doi.org\/10.1038\/s41598-024-70124-z.","DOI":"10.1038\/s41598-024-70124-z"},{"key":"3400_CR3","doi-asserted-by":"publisher","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. May 2019;39(1):19\u201331. https:\/\/doi.org\/10.1111\/liv.14095.","DOI":"10.1111\/liv.14095"},{"key":"3400_CR4","doi-asserted-by":"publisher","unstructured":"Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvis\u00e9 M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. May 2019;39(1):98\u2013107. https:\/\/doi.org\/10.1111\/liv.14086.","DOI":"10.1111\/liv.14086"},{"key":"3400_CR5","doi-asserted-by":"publisher","unstructured":"El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma, Surg Oncol Clin N Am, vol. 28, no. 4, pp. 587\u2013599, Oct. 2019, https:\/\/doi.org\/10.1016\/j.soc.2019.06.002","DOI":"10.1016\/j.soc.2019.06.002"},{"key":"3400_CR6","doi-asserted-by":"publisher","unstructured":"Zhu WH et al. Jun., Postoperative Complications and Survival Analysis of Surgical Resection for Hilar Cholangiocarcinoma: A Retrospective Study of Fifty-Nine Consecutive Patients, Chin Med Sci J, vol. 35, no. 2, pp. 157\u2013169, 2020, https:\/\/doi.org\/10.24920\/003565","DOI":"10.24920\/003565"},{"key":"3400_CR7","unstructured":"Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma - PubMed. Accessed: Dec. 07, 2024. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/35978598\/"},{"key":"3400_CR8","doi-asserted-by":"publisher","first-page":"1118816","DOI":"10.3389\/fimmu.2023.1118816","volume":"14","author":"L Xu","year":"2023","unstructured":"Xu L, Gao X, Xing J, Guo Z. Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma. Front Immunol. 2023;14:1118816. https:\/\/doi.org\/10.3389\/fimmu.2023.1118816.","journal-title":"Front Immunol"},{"key":"3400_CR9","doi-asserted-by":"publisher","unstructured":"Xiao Y et al. Aug., Emerging therapies in cancer metabolism, Cell Metab, vol. 35, no. 8, pp. 1283\u20131303, 2023, https:\/\/doi.org\/10.1016\/j.cmet.2023.07.006","DOI":"10.1016\/j.cmet.2023.07.006"},{"key":"3400_CR10","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. Oct. 2021;21(10):669\u201380. https:\/\/doi.org\/10.1038\/s41568-021-00378-6.","DOI":"10.1038\/s41568-021-00378-6"},{"key":"3400_CR11","doi-asserted-by":"publisher","unstructured":"Ohshima K, Morii E. Metabolic reprogramming of Cancer cells during tumor progression and metastasis. Metabolites. Jan. 2021;11(1):28. https:\/\/doi.org\/10.3390\/metabo11010028.","DOI":"10.3390\/metabo11010028"},{"key":"3400_CR12","doi-asserted-by":"publisher","unstructured":"Jiang B, et al. Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. Mol Cell. May 2022;82(10):1821\u201335. https:\/\/doi.org\/10.1016\/j.molcel.2022.03.016..e6.","DOI":"10.1016\/j.molcel.2022.03.016"},{"key":"3400_CR13","doi-asserted-by":"publisher","unstructured":"Adhikary G et al. Apr., Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation, Mol Carcinog, vol. 62, no. 4, pp. 438\u2013449, 2023, https:\/\/doi.org\/10.1002\/mc.23497","DOI":"10.1002\/mc.23497"},{"key":"3400_CR14","doi-asserted-by":"publisher","unstructured":"Han Y, et al. YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent manner. Cancer Lett. Oct. 2024;601:217186. https:\/\/doi.org\/10.1016\/j.canlet.2024.217186.","DOI":"10.1016\/j.canlet.2024.217186"},{"key":"3400_CR15","doi-asserted-by":"publisher","unstructured":"Liu H-Y, Zhang H-S, Liu M-Y, Li H-M, Wang X-Y, Wang M. GLS1 depletion inhibited colorectal cancer proliferation and migration via redox\/Nrf2\/autophagy-dependent pathway, Arch Biochem Biophys, vol. 708, p. 108964, Sep. 2021, https:\/\/doi.org\/10.1016\/j.abb.2021.108964","DOI":"10.1016\/j.abb.2021.108964"},{"key":"3400_CR16","doi-asserted-by":"publisher","unstructured":"Yang Y et al. Dec., An immunotherapeutic hydrogel booster inhibits tumor recurrence and promotes wound healing for postoperative management of melanoma, Bioact Mater, vol. 42, pp. 178\u2013193, 2024, https:\/\/doi.org\/10.1016\/j.bioactmat.2024.08.028","DOI":"10.1016\/j.bioactmat.2024.08.028"},{"key":"3400_CR17","doi-asserted-by":"publisher","unstructured":"Song Z, et al. Glutamic oxaloacetic transaminase 1 as a potential target in human cancer. Eur J Pharmacol. Feb. 2022;917:174754. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174754.","DOI":"10.1016\/j.ejphar.2022.174754"},{"key":"3400_CR18","doi-asserted-by":"publisher","unstructured":"Lee B, et al. Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery. Sci Rep. Feb. 2020;10(1):3716. https:\/\/doi.org\/10.1038\/s41598-020-60616-z.","DOI":"10.1038\/s41598-020-60616-z"},{"key":"3400_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fonc.2020.00379","volume":"10","author":"Z Cheng","year":"2020","unstructured":"Cheng Z, et al. Upregulation of Glutamic-Oxaloacetic transaminase 1 predicts poor prognosis in acute myeloid leukemia. Front Oncol. 2020;10:379. https:\/\/doi.org\/10.3389\/fonc.2020.00379.","journal-title":"Front Oncol"},{"key":"3400_CR20","doi-asserted-by":"publisher","unstructured":"Kremer DM, et al. GOT1 Inhibition promotes pancreatic cancer cell death by ferroptosis. Nat Commun. Aug. 2021;12(1):4860. https:\/\/doi.org\/10.1038\/s41467-021-24859-2.","DOI":"10.1038\/s41467-021-24859-2"},{"key":"3400_CR21","doi-asserted-by":"publisher","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer, Nat Rev Cancer, vol. 23, no. 12, pp. 842\u2013862, Dec. 2023, https:\/\/doi.org\/10.1038\/s41568-023-00633-y","DOI":"10.1038\/s41568-023-00633-y"},{"key":"3400_CR22","doi-asserted-by":"publisher","unstructured":"Li J, et al. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity. Nat Commun. Dec. 2022;13(1):7799. https:\/\/doi.org\/10.1038\/s41467-022-35557-y.","DOI":"10.1038\/s41467-022-35557-y"},{"key":"3400_CR23","doi-asserted-by":"publisher","unstructured":"Cai B, et al. USP5 attenuates NLRP3 inflammasome activation by promoting autophagic degradation of NLRP3. Autophagy. May 2022;18(5):990\u20131004. https:\/\/doi.org\/10.1080\/15548627.2021.1965426.","DOI":"10.1080\/15548627.2021.1965426"},{"key":"3400_CR24","doi-asserted-by":"publisher","unstructured":"Xia P, et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun. Jan. 2023;43(3):338. https:\/\/doi.org\/10.1002\/cac2.12403.","DOI":"10.1002\/cac2.12403"},{"key":"3400_CR25","doi-asserted-by":"publisher","unstructured":"Gao S-T, Xin X, Wang Z-Y, Hu Y-Y, Feng Q. USP5: comprehensive insights into structure, function, biological and disease-related implications, and emerging therapeutic opportunities. Mol Cell Probes. Feb. 2024;73:101944. https:\/\/doi.org\/10.1016\/j.mcp.2023.101944.","DOI":"10.1016\/j.mcp.2023.101944"},{"key":"3400_CR26","doi-asserted-by":"publisher","unstructured":"Al-Ali HN et al. Feb., A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo, Oncogene, vol. 43, no. 8, pp. 608\u2013614, 2024, https:\/\/doi.org\/10.1038\/s41388-023-02919-9","DOI":"10.1038\/s41388-023-02919-9"},{"key":"3400_CR27","doi-asserted-by":"publisher","unstructured":"Koese M et al. Jun., Annexin A6 is a scaffold for PKC\u03b1 to promote EGFR inactivation, Oncogene, vol. 32, no. 23, pp. 2858\u20132872, 2013, https:\/\/doi.org\/10.1038\/onc.2012.303","DOI":"10.1038\/onc.2012.303"},{"key":"3400_CR28","doi-asserted-by":"publisher","unstructured":"Gerke V, et al. Annexins-a family of proteins with distinctive tastes for cell signaling and membrane dynamics. Nat Commun. Feb. 2024;15(1):1574. https:\/\/doi.org\/10.1038\/s41467-024-45954-0.","DOI":"10.1038\/s41467-024-45954-0"},{"key":"3400_CR29","doi-asserted-by":"publisher","unstructured":"Fang L, et al. Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity. Signal Transduct Target Ther. Aug. 2024;9(1):218. https:\/\/doi.org\/10.1038\/s41392-024-01930-0.","DOI":"10.1038\/s41392-024-01930-0"},{"key":"3400_CR30","doi-asserted-by":"publisher","unstructured":"Shen X, Zhang S, Guo Z, Xing D, Chen W. The crosstalk of ABCA1 and ANXA1: a potential mechanism for protection against atherosclerosis. Mol Med. Sep. 2020;26(1):84. https:\/\/doi.org\/10.1186\/s10020-020-00213-y.","DOI":"10.1186\/s10020-020-00213-y"},{"key":"3400_CR31","doi-asserted-by":"publisher","unstructured":"Rohwer N, et al. Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget. Feb. 2016;7(6):6693\u2013710. https:\/\/doi.org\/10.18632\/oncotarget.6793.","DOI":"10.18632\/oncotarget.6793"},{"key":"3400_CR32","doi-asserted-by":"publisher","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of Cancer metabolism. Cell Metab. Jan. 2016;23(1):27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","DOI":"10.1016\/j.cmet.2015.12.006"},{"key":"3400_CR33","doi-asserted-by":"publisher","unstructured":"Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma, J Hepatol, vol. 77, no. 3, pp. 849\u2013864, Sep. 2022, https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038","DOI":"10.1016\/j.jhep.2022.04.038"},{"key":"3400_CR34","doi-asserted-by":"publisher","unstructured":"Liang Z, Li X. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer, Autoimmunity, vol. 54, no. 2, pp. 76\u201387, Mar. 2021, https:\/\/doi.org\/10.1080\/08916934.2021.1887148","DOI":"10.1080\/08916934.2021.1887148"},{"key":"3400_CR35","doi-asserted-by":"publisher","unstructured":"Pan C, Li B, Simon MC. Moonlighting functions of metabolic enzymes and metabolites in cancer, Mol Cell, vol. 81, no. 18, pp. 3760\u20133774, Sep. 2021, https:\/\/doi.org\/10.1016\/j.molcel.2021.08.031","DOI":"10.1016\/j.molcel.2021.08.031"},{"key":"3400_CR36","doi-asserted-by":"publisher","unstructured":"Kerk SA, Papagiannakopoulos T, Shah YM, Lyssiotis CA. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment, Nat Rev Cancer, vol. 21, no. 8, pp. 510\u2013525, Aug. 2021, https:\/\/doi.org\/10.1038\/s41568-021-00375-9","DOI":"10.1038\/s41568-021-00375-9"},{"key":"3400_CR37","doi-asserted-by":"publisher","unstructured":"Nwosu ZC, et al. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature. Jun. 2023;618(7963):151\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06073-w.","DOI":"10.1038\/s41586-023-06073-w"},{"key":"3400_CR38","doi-asserted-by":"publisher","unstructured":"Ara\u00fajo TG, Mota STS, Ferreira HSV, Ribeiro MA, Goulart LR, Vecchi L. Annexin A1 as a regulator of immune response in Cancer. Cells. Aug. 2021;10(9):2245. https:\/\/doi.org\/10.3390\/cells10092245.","DOI":"10.3390\/cells10092245"},{"key":"3400_CR39","doi-asserted-by":"publisher","unstructured":"Zheng Y, et al. Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment. Cell Mol Immunol. Dec. 2023;21(1):47. https:\/\/doi.org\/10.1038\/s41423-023-01110-0.","DOI":"10.1038\/s41423-023-01110-0"},{"key":"3400_CR40","doi-asserted-by":"publisher","unstructured":"Cioni B et al. Jun., JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer, Mol Cancer Res, vol. 21, no. 6, pp. 614\u2013627, 2023, https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0370","DOI":"10.1158\/1541-7786.MCR-22-0370"},{"key":"3400_CR41","doi-asserted-by":"publisher","unstructured":"Carr EL et al. Jun., Glutamine Uptake and Metabolism Are Coordinately Regulated by ERK\/MAPK During T Lymphocyte Activation, Journal of immunology (Baltimore, Md.: 1950), vol. 185, no. 2, p. 1037, 2010, https:\/\/doi.org\/10.4049\/jimmunol.0903586","DOI":"10.4049\/jimmunol.0903586"},{"key":"3400_CR42","doi-asserted-by":"publisher","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle, Journal of Experimental & Clinical Cancer Research, vol. 43, no. 1, p. 74, Mar. 2024, https:\/\/doi.org\/10.1186\/s13046-024-02994-0","DOI":"10.1186\/s13046-024-02994-0"},{"key":"3400_CR43","doi-asserted-by":"publisher","unstructured":"Guo C, et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. Aug. 2023;620(7972):200\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06299-8.","DOI":"10.1038\/s41586-023-06299-8"},{"key":"3400_CR44","doi-asserted-by":"publisher","unstructured":"Mennerich D, Kubaichuk K, Kietzmann T. DUBs, hypoxia, and Cancer. Trends Cancer. Oct. 2019;5(10):632\u201353. https:\/\/doi.org\/10.1016\/j.trecan.2019.08.005.","DOI":"10.1016\/j.trecan.2019.08.005"},{"key":"3400_CR45","doi-asserted-by":"publisher","unstructured":"Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. Oct. 2020;19(1):146. https:\/\/doi.org\/10.1186\/s12943-020-01262-x.","DOI":"10.1186\/s12943-020-01262-x"},{"key":"3400_CR46","doi-asserted-by":"publisher","unstructured":"Antao AM, Tyagi A, Kim K-S, Ramakrishna S. Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics, Cancers (Basel), vol. 12, no. 6, p. 1579, Jun. 2020, https:\/\/doi.org\/10.3390\/cancers12061579","DOI":"10.3390\/cancers12061579"},{"key":"3400_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41420-020-0292-1","volume":"6","author":"I Sahin","year":"2020","unstructured":"Sahin I, et al. AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discov. 2020;6:57. https:\/\/doi.org\/10.1038\/s41420-020-0292-1.","journal-title":"Cell Death Discov"},{"key":"3400_CR48","doi-asserted-by":"publisher","unstructured":"Sun D et al. Feb., Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development, J Med Chem, vol. 57, no. 4, pp. 1454\u20131472, 2014, https:\/\/doi.org\/10.1021\/jm401753e","DOI":"10.1021\/jm401753e"},{"key":"3400_CR49","doi-asserted-by":"publisher","unstructured":"Wei J et al. Sep., Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation, J Am Chem Soc, vol. 143, no. 37, pp. 15073\u201315083, 2021, https:\/\/doi.org\/10.1021\/jacs.1c04841","DOI":"10.1021\/jacs.1c04841"},{"key":"3400_CR50","doi-asserted-by":"publisher","unstructured":"Efficacy. of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.| Journal of Clinical Oncology. Accessed: Apr. 16, 2025. [Online]. Available: https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.590","DOI":"10.1200\/JCO.2022.40.4_suppl.590"},{"key":"3400_CR51","unstructured":"A trial looking at MDX-124 for solid tumours that have spread (ATTAINMENT). Cancer Research UK. Accessed: Apr. 15, 2025. [Online]. Available: https:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial\/a-trial-looking-at-mdx-124-for-solid-tumours-that-have-spread-attainment"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03400-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:59:52Z","timestamp":1747627192000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03400-z","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported by the ethics committee of the first affiliated hospital of Guizhou Medical University and the Animal Care and Treatment Committee of Guizhou Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agreed to publish the study in the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"relationships that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}